BAFNA PHARMACEUTICALS LTD
BAFNAPH · General/Diversified · NSE
₹165
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for BAFNAPH yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
5/9
Economic Moat
None
Confidence
32%
ROE
11.5%
Debt/Equity
0.39
WACC
11.1%
Market Cap
₹391.39 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
15.5%
Return on capital employed
EV / EBITDA
21.7×
Enterprise multiple
Debt / EBITDA
2.3×
Leverage vs earnings
Interest Coverage
2.6×
EBIT covers interest
Current Ratio
1.63×
Short-term liquidity
Asset Turnover
0.98×
Revenue per ₹ of assets
Revenue CAGR (3Y)
9.3%
3-year revenue growth
Revenue CAGR (5Y)
16.2%
5-year revenue growth
Ratio Trends
BAFNAPH · last 7 annual periods
ROE
11.5%
ROCE
15.5%
Operating Margin
—
Debt / Equity
0.39×
PE
57.4×
EV / EBITDA
27.7×
Historical Financials
BAFNAPH · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹85.1 Cr | ₹115 Cr | ₹152 Cr | ₹146 Cr | ₹151 Cr | +15.3% |
| EBITDA | ₹11.2 Cr | ₹18.7 Cr | ₹14.3 Cr | ₹11.8 Cr | ₹20.7 Cr | +16.5% |
| EBIT | ₹5.9 Cr | ₹13.7 Cr | ₹9.6 Cr | — | — | +12.8% |
| PAT | ₹5.2 Cr | ₹11.3 Cr | ₹7.3 Cr | ₹4.2 Cr | ₹11.1 Cr | +20.8% |
| EPS (diluted) | ₹2.17 | ₹4.86 | ₹3.11 | — | — | +9.4% |
| CFO | ₹9.7 Cr | ₹5.0 Cr | ₹9.5 Cr | ₹22.1 Cr | ₹15.4 Cr | +12.1% |
| CapEx | ₹-7.5 Cr | ₹-8.2 Cr | ₹-15.8 Cr | ₹-21.9 Cr | ₹-24.9 Cr | — |
| FCF | ₹2.2 Cr | ₹-3.3 Cr | ₹-6.4 Cr | ₹0.3 Cr | ₹-9.5 Cr | — |
| Total Assets | ₹90.1 Cr | ₹130 Cr | ₹148 Cr | ₹153 Cr | ₹176 Cr | +18.1% |
| Total Debt | ₹11.1 Cr | ₹22.9 Cr | ₹24.4 Cr | ₹28.2 Cr | ₹37.4 Cr | +35.6% |
| Shareholders' Equity | ₹62.0 Cr | ₹73.5 Cr | ₹80.8 Cr | ₹84.8 Cr | ₹96.1 Cr | +11.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
BAFNAPH vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
ALBERTDAVD ALBERTDAVD | — | — | Pending | -0.4% | — |
VALIANTLAB VALIANTLAB | — | — | Pending | -0.9% | — |
MEDICO MEDICO | — | — | Pending | 17.4% | — |
MEDICAMEQ MEDICAMEQ | — | — | Pending | 3.4% | — |
AMANTA AMANTA | — | — | Pending | 6.8% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for BAFNAPH in the last 10 years.
Risk Analysis
Volatility & drawdown
Risk profile of BAFNAPH →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for BAFNAPH →
Compare
Head-to-head with peers
Compare BAFNAPH side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse BAFNAPHNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.